{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:22:22Z","timestamp":1793388142643,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["grant n. 667946"],"award-info":[{"award-number":["grant n. 667946"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40259-020-00415-0","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T14:02:44Z","timestamp":1584712964000},"page":"265-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies"],"prefix":"10.1007","volume":"34","author":[{"given":"Luigia","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pierig\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia Paolo","family":"Aliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6456-6626","authenticated-orcid":false,"given":"Mauro","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,20]]},"reference":[{"key":"415_CR1","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1073\/pnas.70.9.2663","volume":"70","author":"GM Ihler","year":"1973","unstructured":"Ihler GM, Glew RH, Schnure FW. Enzyme loading of erythrocytes. Proc Natl Acad Sci USA. 1973;70:2663\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"415_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1085\/jgp.42.1.9","volume":"42","author":"JF Hoffman","year":"1958","unstructured":"Hoffman JF. Physiological characteristics of human red blood cell ghosts. J Gen Physiol. 1958;42:9\u201328.","journal-title":"J Gen Physiol"},{"key":"415_CR3","first-page":"1","volume":"326","author":"JF Hoffman","year":"1992","unstructured":"Hoffman JF. On red blood cells, hemolysis and resealed ghosts. Adv Exp Med Biol. 1992;326:1\u201315.","journal-title":"Adv Exp Med Biol"},{"key":"415_CR4","first-page":"1","volume":"51","author":"JR DeLoach","year":"1985","unstructured":"DeLoach JR. Hypotonic dialysis encapsulation in erythrocytes of mammalian species. Bibl Haematol. 1985;51:1\u20136.","journal-title":"Bibl Haematol."},{"key":"415_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1454","author":"F Pierige","year":"2017","unstructured":"Pierige F, Bigini N, Rossi L, Magnani M. Reengineering red blood cells for cellular therapeutics and diagnostics. WIREs Nanomed Nanobiotechnol. 2017. https:\/\/doi.org\/10.1002\/wnan.1454.","journal-title":"WIREs Nanomed Nanobiotechnol."},{"key":"415_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.addr.2016.02.007","volume":"106","author":"CH Villa","year":"2016","unstructured":"Villa CH, Anselmo AC, Mitragotri S, Muzykantov V. Red blood cells: supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems. Adv Drug Deliv Rev. 2016;106:88\u2013103.","journal-title":"Adv Drug Deliv Rev"},{"key":"415_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01070","author":"L Rossi","year":"2019","unstructured":"Rossi L, Fraternale A, Bianchi M, Magnani M. Red blood cell membrane processing for biomedical applications. Front Physiol. 2019. https:\/\/doi.org\/10.3389\/fphys.2019.01070.","journal-title":"Front Physiol"},{"key":"415_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.actbio.2019.10.027","volume":"101","author":"W Ji","year":"2020","unstructured":"Ji W, Smith PN, Koepsel RR, Andersen JD, Baker SL, Zhang L, Carmali S, Myerson JW, Muzykantov S, Russell AJ. Erythrocytes as carriers of immunoglobulin-based therapeutics. Acta Biomater. 2020;101:422\u201335. https:\/\/doi.org\/10.1016\/j.actbio.2019.10.027.","journal-title":"Acta Biomater."},{"issue":"3","key":"415_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1182\/bloodadvances.2017011734","volume":"2","author":"CH Villa","year":"2018","unstructured":"Villa CH, Pan DC, Johnston IH, Greineder CF, Walsh LR, Hood ED, Cines DB, Poncz M, Siegel DL, Muzykantov VR. Biocompatible coupling of therapeutic fusion proteins to human erythrocytes. Blood Adv. 2018;2(3):165\u201376. https:\/\/doi.org\/10.1182\/bloodadvances.2017011734.","journal-title":"Blood Adv."},{"issue":"4","key":"415_CR10","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1021\/acs.bioconjchem.7b00758","volume":"29","author":"X Han","year":"2018","unstructured":"Han X, Wang C, Liu Z. Red blood cells as smart delivery systems. Bioconjug Chem. 2018;29(4):852\u201360. https:\/\/doi.org\/10.1021\/acs.bioconjchem.7b00758.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"415_CR11","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1038\/s41467-018-05079-7","volume":"9","author":"JS Brenner","year":"2018","unstructured":"Brenner JS, Pan DC, Myerson JW, Marcos-Contreras OA, Villa CH, Patel P, Hekierski H, Chatterjee S, Tao JQ, Parhiz H, Bhamidipati K, Uhler TG, Hood ED, Kiseleva RY, Shuvaev VS, Shuvaeva T, Khoshnejad M, Johnston I, Gregory JV, Lahann J, Wang T, Cantu E, Armstead WM, Mitragotri S, Muzykantov V. Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude. Nat Commun. 2018;9(1):2684. https:\/\/doi.org\/10.1038\/s41467-018-05079-7.","journal-title":"Nat Commun."},{"issue":"1","key":"415_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1470-8744.1998.tb00505.x","volume":"28","author":"M Magnani","year":"1998","unstructured":"Magnani M, Rossi L, D\u2019ascenzo M, Panzani I, Bigi L, Zanella A. Erythrocyte engineering for drug delivery and targeting. Biotechnol Appl Biochem. 1998;28(1):1\u20136.","journal-title":"Biotechnol Appl Biochem."},{"issue":"1\u20132","key":"415_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ijpharm.2016.12.011","volume":"517","author":"G Mambrini","year":"2017","unstructured":"Mambrini G, Mandolini M, Rossi L, Pierig\u00e8 F, Capogrossi G, Salvati P, Serafini S, Benatti L, Magnani M. Ex vivo encapsulation of dexamethasone sodium phosphate into human autologous erythrocytes using fully automated biomedical equipment. Int J Pharm. 2017;517(1\u20132):175\u201384.","journal-title":"Int J Pharm."},{"issue":"2","key":"415_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.tmrv.2017.09.001","volume":"32","author":"SA Coker","year":"2018","unstructured":"Coker SA, Szczepiorkowski ZM, Siegel AH, Ferrari A, Mambrini G, Anand R, Hartman RD, Benatti L, Dumont LJ. A study of the pharmacokinetic properties and the in vivo kinetics of erythrocytes loaded with dexamethasone sodium phosphate in healthy volunteers. Transfus Med Rev. 2018;32(2):102\u201310.","journal-title":"Transfus Med Rev."},{"issue":"2","key":"415_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1042\/BA20000087","volume":"33","author":"L Rossi","year":"2001","unstructured":"Rossi L, Serafini S, Cenerini L, Picardi F, Bigi L, Panzani I, Magnani M. Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease. Biotechnol Appl Biochem. 2001;33(2):85\u20139.","journal-title":"Biotechnol Appl Biochem"},{"issue":"1","key":"415_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.bcmd.2004.04.004","volume":"33","author":"L Rossi","year":"2004","unstructured":"Rossi L, Castro M, D\u2019Orio F, Damonte G, Serafini S, Bigi L, Panzani I, Novelli G, Dallapiccola B, Panunzi S, Di Carlo P, Bella S, Magnani M. Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. Blood Cells Mol Dis. 2004;33(1):57\u201363.","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"415_CR17","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1111\/j.1572-0241.2005.41412.x","volume":"100","author":"V Annese","year":"2005","unstructured":"Annese V, Latiano A, Rossi L, Lombardi G, Dallapiccola B, Serafini S, Damonte G, Andriulli A, Magnani M. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients\u2014a pilot uncontrolled study. Am J Gastroenterol. 2005;100(6):1370\u20135.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"415_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/01.mpg.0000188006.59128.47","volume":"42","author":"M Castro","year":"2006","unstructured":"Castro M, Knafelz D, Rossi L, Ambrosini MI, Papadatou B, Mambrini G, Magnani M. Periodic treatment with autologous erythrocytes loaded with dexamethasone 21-phosphate for fistulizing pediatric Crohn\u2019s disease: case report. J Pediatr Gastroenterol Nutr. 2006;42(3):313\u20135.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"415_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/MPG.0b013e3180320667","volume":"44","author":"M Castro","year":"2007","unstructured":"Castro M, Rossi L, Papadatou B, Bracci F, Knafelz D, Ambrosini MI, Calce A, Serafini S, Isacchi G, D\u2019Orio F, Mambrini G, Magnani M. Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn disease. J Pediatr Gastroenterol Nutr. 2007;44(4):423\u20136.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"10","key":"415_CR20","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1111\/j.1572-0241.2008.02103.x","volume":"103","author":"F Bossa","year":"2008","unstructured":"Bossa F, Latiano A, Rossi L, Magnani M, Palmieri O, Dallapiccola B, Serafini S, Damonte G, De Santo E, Andriulli A, Annese V. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol. 2008;103(10):2509\u201316.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"415_CR21","first-page":"1872","volume":"19","author":"F Bossa","year":"2013","unstructured":"Bossa F, Annese V, Valvano MR, Latiano A, Martino G, Rossi L, Magnani M, Palmieri O, Serafini S, Damonte G, De Santo E, Andriulli A. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis. 2013;19(9):1872\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"415_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-5","author":"L Chessa","year":"2014","unstructured":"Chessa L, Leuzzi V, Plebani A, Soresina A, Micheli R, D\u2019Agnano D, Venturi T, Molinaro A, Fazzi E, Marini M, Ferremi Leali P, Quinti I, Cavaliere FM, Girelli G, Pietrogrande MC, Finocchi A, Tabolli S, Abeni D, Magnani M. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial. Orphanet J Rare Dis. 2014. https:\/\/doi.org\/10.1186\/1750-1172-9-5.","journal-title":"Orphanet J Rare Dis."},{"issue":"4254","key":"415_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1126\/science.821145","volume":"193","author":"SJ Updike","year":"1976","unstructured":"Updike SJ, Wakamiya RT, Lightfoot EN Jr. Asparaginase entrapped in red blood cells: action and survival. Science. 1976;193(4254):681\u20133.","journal-title":"Science"},{"issue":"5","key":"415_CR24","first-page":"679","volume":"101","author":"SJ Updike","year":"1983","unstructured":"Updike SJ, Wakamiya RT. Infusion of red blood cell-loaded asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences. J Lab Clin Med. 1983;101(5):679\u201391.","journal-title":"J Lab Clin Med."},{"issue":"3\u20134","key":"415_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s002280050187","volume":"51","author":"R Kravtzoff","year":"1996","unstructured":"Kravtzoff R, Colombat PH, Desbois I, Linassier C, Muh JP, Philip T, Blay JY, Gardenbas M, Poumier-Gaschard P, Lamagnere JP, Chassaigne M, Ropars C. Tolerance evaluation of l-asparaginase loaded in red blood cells. Eur J Clin Pharmacol. 1996;51(3\u20134):221\u20135.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"415_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/BF00195932","volume":"49","author":"R Kravtzoff","year":"1996","unstructured":"Kravtzoff R, Desbois I, Lamagnere JP, Muh JP, Valat C, Chassaigne M, Colombat P, Ropars C. Improved pharmacodynamics of L-asparaginase loaded in human red blood cells. Eur J Clin Pharmacol. 1996;49(6):465\u201370.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"415_CR27","first-page":"807","volume":"33","author":"MI Gar\u00edn","year":"1994","unstructured":"Gar\u00edn MI, Kravtzoff R, Chestier N, Sanz S, Pinilla M, Luque J, Ropars C. Density gradient separation of l-asparaginase-loaded human erythrocytes. Biochem Mol Biol Int. 1994;33(4):807\u201314.","journal-title":"Biochem Mol Biol Int"},{"key":"415_CR28","first-page":"175","volume":"326","author":"R Ktavtzoff","year":"1992","unstructured":"Ktavtzoff R, Desbois I, Doinel C, Colombat P, Lamagnere JP, Chassaigne M, Ropars C. Immunological response to l-asparaginase loaded into red blood cells. Adv Exp Med Biol. 1992;326:175\u201382.","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"415_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.2042-7158.1990.tb06598.x","volume":"42","author":"R Kravtzoff","year":"1990","unstructured":"Kravtzoff R, Ropars C, Laguerre M, Muh JP, Chassaigne M. Erythrocytes as carriers for l-asparaginase. Methodological and mouse in vivo studies. J Pharm Pharmacol. 1990;42(7):473\u20136.","journal-title":"J Pharm Pharmacol."},{"issue":"1","key":"415_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1365-2141.2011.08588.x","volume":"153","author":"C Domenech","year":"2011","unstructured":"Domenech C, Thomas X, Chabaud S, Baruchel A, Gueyffier F, Mazingue F, Auvrignon A, Corm S, Dombret H, Chevallier P, Galambrun C, Huguet F, Legrand F, Mechinaud F, Vey N, Philip I, Liens D, Godfrin Y, Rigal D, Bertrand Y. l-Asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011;153(1):58\u201365.","journal-title":"Br J Haematol"},{"issue":"9","key":"415_CR31","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/ajh.24093","volume":"90","author":"M Hunault-Berger","year":"2015","unstructured":"Hunault-Berger M, Leguay T, Huguet F, Lepr\u00eatre S, Deconinck E, Ojeda-Uribe M, Bonmati C, Escoffre-Barbe M, Bories P, Himberlin C, Chevallier P, Rousselot P, Reman O, Boulland ML, Lissandre S, Turlure P, Bouscary D, Sanhes L, Legrand O, Lafage-Pochitaloff M, B\u00e9n\u00e9 MC, Liens D, Godfrin Y, Ifrah N, Dombret H, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). A phase 2 study of l-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: the GRASPALL\/GRAALL-SA2-2008 study. Am J Hematol. 2015;90(9):811\u20138.","journal-title":"Am J Hematol."},{"issue":"7","key":"415_CR32","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/MPA.0000000000000394","volume":"44","author":"JB Bachet","year":"2015","unstructured":"Bachet JB, Gay F, Mar\u00e9chal R, Galais MP, Adenis A, MsC DS, Cros J, Demetter P, Svrcek M, Bardier-Dupas A, Emile JF, Hammel P, Ebenezer C, Berlier W, Godfrin Y, Andr\u00e9 T. Asparagine synthetase expression and phase I study with l-asparaginase encapsulated in red blood cells in patients with pancreatic adenocarcinoma. Pancreas. 2015;44(7):1141\u20137.","journal-title":"Pancreas"},{"key":"415_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2019.10.020","volume":"124","author":"P Hammel","year":"2019","unstructured":"Hammel P, Fabienne P, Mineur L, Metges JP, Andre T, De La Fouchardiere C, Louvet C, El Hajbi F, Faroux R, Guimbaud R, Tougeron D, Bouche O, Lecomte T, Rebischung C, Tournigand C, Cros J, Kay R, Hamm A, Gupta A, Bachet JB, El Hariry I. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: an open-label, randomized Phase IIb trial. Eur J Cancer. 2019;124:91\u2013101.","journal-title":"Eur J Cancer"},{"issue":"9","key":"415_CR34","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1212\/01.wnl.0000324602.97205.ab","volume":"71","author":"NF Moran","year":"2008","unstructured":"Moran NF, Bain MD, Muqit MM, Bax BE. Carrier erythrocyte entrapped thymidine phosphorylase therapy for MNGIE. Neurology. 2008;71(9):686\u20138.","journal-title":"Neurology"},{"issue":"14","key":"415_CR35","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1212\/WNL.0b013e3182a6cb4b","volume":"81","author":"BE Bax","year":"2013","unstructured":"Bax BE, Bain MD, Scarpelli M, Filosto M, Tonin P, Moran N. Clinical and biochemical improvements in a patient with MNGIE following enzyme replacement. Neurology. 2013;81(14):1269\u201371.","journal-title":"Neurology."},{"key":"415_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8040457","author":"M Levene","year":"2019","unstructured":"Levene M, Bain MD, Moran NF, Nirmalananthan N, Poulton J, Scarpelli M, Filosto M, Mandel H, MacKinnon AD, Fairbanks L, Pacitti D, Bax BE. Safety and efficacy of erythrocyte encapsulated thymidine phosphorylase in mitochondrial neurogastrointestinal encephalomyopathy. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8040457.","journal-title":"J Clin Med."},{"key":"415_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081096","author":"BE Bax","year":"2019","unstructured":"Bax BE, Levene M, Bain MD, Fairbanks LD, Filosto M, Kalkan U\u00e7ar S, Klopstock T, Kornblum C, Mandel H, Rahman S, Roubertie A, Scarpelli M, Sedgwick PM, Baru M, Sellos-Moura M, Price J, Horn P, Nirmalananthan N. Erythrocyte encapsulated thymidine phosphorylase for the treatment of patients with mitochondrial neurogastrointestinal encephalomyopathy: study protocol for a multi-centre, multiple dose, open label trial. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8081096.","journal-title":"J Clin Med."},{"key":"415_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2018.00669","author":"D Pacitti","year":"2018","unstructured":"Pacitti D, Levene M, Garone C, Nirmalananthan N, Bax BE. Mitochondrial neurogastrointestinal encephalomyopathy: into the fourth decade, what we have learned so far. Front Genet. 2018. https:\/\/doi.org\/10.3389\/fgene.2018.00669.","journal-title":"Front Genet."},{"issue":"4","key":"415_CR39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/87565641.2016.1243109","volume":"41","author":"DA Bilder","year":"2016","unstructured":"Bilder DA, Noel JK, Baker ER, Irish W, Chen Y, Merilainen MJ, Prasad S, Winslow BJ. Systematic review and meta-analysis of neuropsychiatric symptoms and executive functioning in adults with phenylketonuria. Dev Neuropsychol. 2016;41(4):245\u201360.","journal-title":"Dev Neuropsychol"},{"key":"415_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2019-106278","author":"V Leuzzi","year":"2019","unstructured":"Leuzzi V, Chiarotti F, Nardecchia F, van Vliet D, van Spronsen FJ. Predictability and inconsistencies of cognitive outcome in patients with phenylketonuria and personalised therapy: the challenge for the future guidelines. J Med Genet. 2019. https:\/\/doi.org\/10.1136\/jmedgenet-2019-106278.","journal-title":"J Med Genet"},{"key":"415_CR41","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ebiom.2018.10.038","volume":"37","author":"S Gupta","year":"2018","unstructured":"Gupta S, Lau K, Harding CO, Shepherd G, Boyer R, Atkinson JP, Knight V, Olbertz J, Larimore K, Gu Z, Li M, Rosen O, Zoog SJ, Weng HH, Schweighardt B. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. EBioMedicine. 2018;37:366\u201373.","journal-title":"EBioMedicine"},{"key":"415_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jconrel.2014.08.012","volume":"194","author":"L Rossi","year":"2014","unstructured":"Rossi L, Pierig\u00e8 F, Carducci C, Gabucci C, Pascucci T, Canonico B, Bell SM, Fitzpatrick PA, Leuzzi V, Magnani M. Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBR-Pah(enu2) mice. J Control Release. 2014;194:37\u201344.","journal-title":"J Control Release"},{"issue":"1","key":"415_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ymgme.2018.03.009","volume":"124","author":"T Pascucci","year":"2018","unstructured":"Pascucci T, Rossi L, Colamartino M, Gabucci C, Carducci C, Valzania A, Sasso V, Bigini N, Pierig\u00e8 F, Viscomi MT, Ventura R, Cabib S, Magnani M, Puglisi-Allegra S, Leuzzi V. A new therapy prevents intellectual disability in mouse with phenylketonuria. Mol Genet Metab. 2018;124(1):39\u201349.","journal-title":"Mol Genet Metab"},{"key":"415_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1454","author":"F Pierig\u00e8","year":"2017","unstructured":"Pierig\u00e8 F, Bigini N, Rossi L, Magnani M. Reengineering red blood cells for cellular therapeutics and diagnostics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017. https:\/\/doi.org\/10.1002\/wnan.1454.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol."},{"issue":"Pt A","key":"415_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.addr.2016.05.008","volume":"106","author":"L Rossi","year":"2016","unstructured":"Rossi L, Pierig\u00e8 F, Antonelli A, Bigini N, Gabucci C, Peiretti E, Magnani M. Engineering erythrocytes for the modulation of drugs\u2019 and contrasting agents\u2019 pharmacokinetics and biodistribution. Adv Drug Deliv Rev. 2016;106(Pt A):73\u201387.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"415_CR46","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10545-016-9926-0","volume":"39","author":"V Leuzzi","year":"2016","unstructured":"Leuzzi V, Rossi L, Gabucci C, Nardecchia F, Magnani M. Erythrocyte-mediated delivery of recombinant enzymes. J Inherit Metab Dis. 2016;39(4):519\u201330.","journal-title":"J Inherit Metab Dis"},{"key":"415_CR47","first-page":"7","volume":"51","author":"U Sprandel","year":"1985","unstructured":"Sprandel U. Erythrocytes as carrier for therapeutic enzymes\u2014an approach towards enzyme therapy of inborn errors of metabolism. Bibl Haematol. 1985;51:7\u201314.","journal-title":"Bibl Haematol."},{"key":"415_CR48","first-page":"309","volume-title":"Encyclopedia of nanoscience and nanotechnology","author":"M Magnani","year":"2011","unstructured":"Magnani M, Serafini S, Fraternale A, Antonelli A, Biagiotti S, Pierig\u00e8 F, Sfara C, Rossi L. Red blood cell-based delivery of drugs and nanomaterials for therapeutic and diagnostic applications. In: Nalwa HS, editor. Encyclopedia of nanoscience and nanotechnology. New York: American Scientific Publishers; 2011. p. 309\u201354."},{"key":"415_CR49","unstructured":"A new era in cellular medicine. Rubius Therapeutics, Inc. 2019. https:\/\/ir.rubiustx.com\/static-files\/d5ef2cfc-3c34-4950-ac6f-b03ca9ff11e4. Accessed 3 Mar 2020."},{"key":"415_CR50","unstructured":"Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria (press release). Rubius Therapeutics, Inc., 11 Mar 2019. https:\/\/www.globenewswire.com\/news-release\/2019\/03\/11\/1751139\/0\/en\/Rubius-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-First-Ever-Red-Cell-Therapeutic-RTX-134-for-Treatment-of-Phenylketonuria.html. Accessed 3 Mar 2020."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00415-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-020-00415-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00415-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T16:33:54Z","timestamp":1722616434000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-020-00415-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["415"],"URL":"https:\/\/doi.org\/10.1007\/s40259-020-00415-0","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,20]]},"assertion":[{"value":"20 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was partially supported by Horizon 2020 IEDAT Grant n. 667946.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mauro Magnani and Luigia Rossi hold shares in EryDel SpA, a company with interests in the technology of RBC-based drug delivery. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}